Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740317 | 0.98 | TSHR (0.44) | TSHRALDH1A1THRB | |
| SCHEMBL11572579 | 0.93 | — | — | |
| SCHEMBL1829977 | 0.77 | TSHR (0.44) | TSHRALDH1A1THRB | |
| SCHEMBL438729 | 0.76 | TSHR (0.44) | TSHRALDH1A1THRB | |
| SCHEMBL437976 | 0.76 | TSHR (0.44) | TSHRALDH1A1THRB | |
| SCHEMBL17966464 | 0.75 | TSHR (0.50) | TSHRALDH1A1THRB | |
| SCHEMBL10964556 | 0.75 | TSHR (0.41) | TSHRALDH1A1THRB | |
| SCHEMBL17088163 | 0.75 | TSHR (0.50) | TSHRALDH1A1THRB | |
| SCHEMBL18784860 | 0.75 | TSHR (0.50) | TSHRALDH1A1THRB | |
| SCHEMBL18784873 | 0.75 | TSHR (0.50) | TSHRALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106061258-A | Methods of making 2-halonicotinonitriles | 弗吉尼亚联邦大学 | 2016-10-26 | — | — | CN | claimed |
| US-20190216934-A9 | Vitamin-Receptor Binding Drug Delivery Conjugates | ENDOCYTE INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190105399-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | ENDOCYTE INC (US) | 2019-04-11 | — | — | US | disclosed |
| CN-106061258-A | Methods of making 2-halonicotinonitriles | 弗吉尼亚联邦大学 | 2016-10-26 | — | — | CN | disclosed |
| US-20160220694-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | ENDOCYTE INC (US) | 2016-08-04 | — | — | US | disclosed |
| US-9035041-B2 | Process for triphosphate oligonucleotide synthesis | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8765096-B2 | Methods and compositions for treating and diagnosing kidney disease | ENDOCYTE, INC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | ENDOCYTE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2529758-A2 | Vitamin receptor binding drug delivery conjugates | Endocyte, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2517730-A2 | Vitamin receptor binding drug delivery conjugates | Endocyte, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2010045584-A1 | FOLATE TARGETING OF NUCLEOTIDES | ENDOCYTE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2009052191-A1 | INTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099253-A1 | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use | XENOPORT, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008101231-A2 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1592457-A2 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | Endocyte, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050002942-A1 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004069159-A2 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | ENDOCYTE, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-4071498-A | METHYLVINYLDI-(EPSILON-CAPROLACTAMO)SILANE | DOW CORNING CORPORATION (US) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | TSHR 377/4885ALDH1A1 931/4885THRB 694/4885 |
| US-20050002942-A1 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | VDR, CYP2R1, CYP24A1 | TSHR 557/4885ALDH1A1 852/4885THRB 611/4885 |
| US-20160220694-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | VDR, CYP2R1, CYP24A1 | TSHR 371/4885ALDH1A1 672/4885THRB 614/4885 |
| US-20140058063-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | TSHR 377/4885ALDH1A1 931/4885THRB 694/4885 |
| US-20190216934-A9 | Vitamin-Receptor Binding Drug Delivery Conjugates | VDR, CYP2R1, CYP24A1 | TSHR 371/4885ALDH1A1 672/4885THRB 614/4885 |
| US-20090099253-A1 | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use | SI, AASDHPPT, PSAP | TSHR 2722/4885ALDH1A1 930/4885THRB 2615/4885 |
| US-20190105399-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | VDR, CYP2R1, CYP24A1 | TSHR 371/4885ALDH1A1 672/4885THRB 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.